Follow The Filings

TVTX Travere Therapeutics Inc.

Health Care, filed as TRAVERE THERAPEUTICS INC (COM), Equity As of 2026 Q3 so far: 135 of 140 managers we track have filed Quote on Google Finance, opens in a new tab

Bought by 1 manager in 2026 Q3, sold by 1

  • 2 Owners
  • Max 1.4%
  • $12M
  • 1 add 1 reduce

In 2026 Q3 Polen Capital Management added to Travere Therapeutics, while Palo Alto Investors trimmed.

Who owns this now

Largest portfolio weights among holders, up to 1.4% (Palo Alto Investors). Not free-float ownership.

  1. Palo Alto Investors Reduce 1.4%
  2. Polen Capital Management Add 0.03%

Who owns TVTX

Sorted by value, long equity only, as of 2026 Q3.

History
Palo Alto Investors 1.4% Reduce −5.1% 158,946 $9.4M History
Polen Capital Management 0.03%, was <0.01% Add +54.4% 52,988 $3.1M History

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by TVTX's executives, directors and 10% owners in the last 12 months, from their Form 4s

All TVTX insider trades
  • None no insider bought on the open market
  • None no sales outside a trading plan
  • $99.1M sold by 11 insiders under 10b5-1 plans
  1. Eric M. Dube CEO
    Planned sale
    $13.1M 243,735 shares at $53.82 36% of stake
    Traded Oct 15 Filed Oct 19
  2. Christopher R. Cline CFO
    Planned sale
    $3.1M 50,508 shares at $62.34 37% of stake
    Traded Sep 15 Filed Sep 17
  3. Jula Inrig EVP, Head of R&D & CMO
    Planned sale
    $2.8M 44,674 shares at $62.34 31% of stake
    Traded Sep 15 Filed Sep 17
  4. Sandra Calvin SVP, Chief Accounting Officer
    Planned sale
    $335K 5,375 shares at $62.33 11% of stake
    Traded Sep 15 Filed Sep 17
  5. Peter Heerma EVP, Chief Commercial Officer
    Planned sale
    $17.9M 283,189 shares at $63.06 71% of stake
    Traded Sep 15–17 Filed Sep 17
  6. Eric M. Dube CEO
    Planned sale
    $25.4M 400,000 shares at $63.48 48% of stake
    Traded Sep 15–17 Filed Sep 17
  7. William E. Rote Chief Research Officer
    Planned sale
    $13.1M 209,048 shares at $62.83 68% of stake
    Traded Sep 15–16 Filed Sep 17
  8. Elizabeth E. Reed Chief Legal Officer and GC
    Planned sale
    $2.3M 37,500 shares at $62.34 26% of stake
    Traded Sep 15 Filed Sep 17
  9. Jeffrey A. Meckler Director
    Planned sale
    $1.3M 20,000 shares at $67.31 18% of stake
    Traded Sep 10 Filed Sep 11
  10. Gary A. Lyons Director
    Planned sale
    $633K 10,000 shares at $63.28 14% of stake
    Traded Aug 17–18 Filed Aug 19
  11. Roy D. Baynes Director
    Planned sale
    $225K 4,500 shares at $50.00 9.8% of stake
    Traded Jun 12 Filed Jun 16
  12. Timothy Coughlin Director
    Planned sale
    $501K 10,000 shares at $50.07 15% of stake
    Traded Jun 12 Filed Jun 16
  13. Timothy Coughlin Director
    Planned sale
    $141K 3,250 shares at $43.49 5.9% of stake
    Traded May 15 Filed May 19
  14. Jula Inrig Chief Medical Officer
    Planned sale
    $900K 20,000 shares at $45.00 15% of stake
    Traded May 4 Filed May 6
  15. Roy D. Baynes Director
    Planned sale
    $210K 4,500 shares at $46.65 11% of stake
    Traded May 5 Filed May 6

Also filed in the last 12 months, not counted as buying or selling: 64 option exercises, 40 sales to cover taxes, 22 stock grants, and 1 gift.

SEC filings

Recent issuer filings from EDGAR, 16 shown.

Filed Form Detail Links
SCHEDULE 13G/A —
SCHEDULE 13G/A —
10-Q
8-K 2.02,9.01
8-K 5.02,9.01
SCHEDULE 13G/A —
SCHEDULE 13G —
SCHEDULE 13G —
SCHEDULE 13G/A —
8-K 2.02,9.01
10-Q
8-K 5.02
8-K 5.02
8-K 1.01,9.01
8-K 5.02,5.07,9.01
SCHEDULE 13G —

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Revenue $145.24M $233.18M $490.73M
Gross profit * $133.79M $225.43M $480.39M
Gross margin * 92.1% 96.7% 97.9%
Net income -$111.4M -$321.54M -$25.55M
Net margin * -76.7% -137.9% -5.2%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $616.78M $416.7M $437.56M
Total non-current assets * $172.14M $177.42M $167.63M
Total assets $788.91M $594.12M $605.19M
Total current liabilities $177.91M $200.75M $159.9M
Total non-current liabilities * $410.2M $334.3M $330.46M
Total equity $200.81M $59.08M $114.83M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$280.02M -$237.48M $37.78M
Cash from investing $55.78M $99.32M $27.89M
Cash from financing $218.75M $139.42M -$33.47M
Net change in cash -$3.51M $0.359M $34.5M

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.

Further reading

As an Amazon Associate, FollowTheFilings earns from qualifying purchases.

More on the shelf